TY - JOUR
T1 - NAFLD Preclinical Models
T2 - More than a Handful, Less of a Concern?
AU - Oligschlaeger, Yvonne
AU - Shiri-Sverdlov, Ronit
N1 - Funding Information:
Funding: This research was funded by the Dutch Organization for Scientific Research (NWO; VIDI grant no. 016.126.327), ASPASIA (grant no. 015.008.043) and TKI-LSH (grant no. 40-41200-98-9306).
Publisher Copyright:
© 2020 by the authors.
PY - 2020/2
Y1 - 2020/2
N2 - Non-alcoholic fatty liver disease (NAFLD) is a spectrum of liver diseases ranging from simple steatosis to non-alcoholic steatohepatitis, fibrosis, cirrhosis, and/or hepatocellular carcinoma. Due to its increasing prevalence, NAFLD is currently a major public health concern. Although a wide variety of preclinical models have contributed to better understanding the pathophysiology of NAFLD, it is not always obvious which model is best suitable for addressing a specific research question. This review provides insights into currently existing models, mainly focusing on murine models, which is of great importance to aid in the identification of novel therapeutic options for human NAFLD.
AB - Non-alcoholic fatty liver disease (NAFLD) is a spectrum of liver diseases ranging from simple steatosis to non-alcoholic steatohepatitis, fibrosis, cirrhosis, and/or hepatocellular carcinoma. Due to its increasing prevalence, NAFLD is currently a major public health concern. Although a wide variety of preclinical models have contributed to better understanding the pathophysiology of NAFLD, it is not always obvious which model is best suitable for addressing a specific research question. This review provides insights into currently existing models, mainly focusing on murine models, which is of great importance to aid in the identification of novel therapeutic options for human NAFLD.
KW - NAFLD
KW - mouse models
KW - multifactorial disease
KW - translational value
KW - FATTY LIVER-DISEASE
KW - ACTIVATED RECEPTOR-ALPHA
KW - CHOLINE-DEFICIENT DIET
KW - NONALCOHOLIC STEATOHEPATITIS
KW - MOUSE MODELS
KW - HEPATOCELLULAR-CARCINOMA
KW - HEPATIC STEATOSIS
KW - CONFERS SUSCEPTIBILITY
KW - METABOLIC SYNDROME
KW - PROSTAGLANDIN E-2
U2 - 10.3390/biomedicines8020028
DO - 10.3390/biomedicines8020028
M3 - (Systematic) Review article
C2 - 32046285
SN - 2227-9059
VL - 8
JO - Biomedicines
JF - Biomedicines
IS - 2
M1 - 28
ER -